New Research Released on Ra Medical Systems, Inc.

An Executive Informational Overview (EIO) is now available on a closely held medical device company, Ra Medical Systems, Inc. The EIO is a 56-page report detailing Ra Medical's business strategy, products, market opportunities, competition, financials, risks, and more. It is available for download below.

Snapshot of Ra Medical

Ra Medical (or “the Company”) is a medical device company commercializing laser therapies for a number of dermatology and vascular diseases. The Company has had over a decade of past success creating and marketing the PHAROS brand excimer laser to treat psoriasis, vitiligo, atopic dermatitis, and leukoderma. Today, Ra Medical is poised to launch a novel laser and catheter system for minimally invasive endovascular treatments that center on the safe, efficacious, and efficient removal of plaque deposits from inside blood vessels. The Company’s patent-pending DABRA catheter design has shown to achieve faster ablation and a higher quality lumen than is currently available. Further, it can be manufactured at a lower cost and uses a powerful, more portable, and more intuitive laser platform than competing products. A U.S. clinical study for the DABRA catheter is presently ongoing, which Ra Medical believes can support a 510(k) medical device clearance leading to the start of sales later in 2016.

10 Key Points of Ra Medical's Business

• Ra Medical creates and commercializes medical devices targeting the dermatology and endovascular specialties. The Company’s core competencies include a deep understanding of the development, manufacture, regulatory pathways, and maintenance of laser systems for medical applications.

• The Company’s first product, the PHAROS EX-308 laser for dermatology markets, has been sold in 18 countries around the world. Ra Medical was able to leverage its initial medical device clearances in psoriasis and vitiligo to also include clearances for additional indications in atopic dermatitis and leukoderma. Though the technology is now in the public domain, Ra Medical has also had successful experience defending its patents on the PHAROS laser in court.

• The Company’s present product development focuses on markets for vascular and cardiovascular diseases, with the anticipated launch during 2016 of a novel excimer laser and catheter solution for endovascular procedures. Development of its RA-308 laser and DABRA catheters has been underway for roughly eight years, with over $65 million invested in creating a new catheter design that may perform endovascular ablation more efficiently, effectively, safely, and rapidly than existing technologies, and at a lower cost.

• Ra Medical believes there exists a compelling strategic opportunity for its DABRA catheters in a very large market. The Company’s newest device is intended to serve as a laser atherectomy adjunct to balloon angioplasty and stents—two procedures commonly used in the treatment of peripheral and coronary artery diseases and conditions, but that are limited in their effectiveness. Up to 15% of patients need to have repeat procedures to reopen their arteries, even after having a stent placed, and many more have complications from the procedure as a result of trauma to the artery from balloon inflation or other causes.

• Atherectomy in conjunction with angioplasty or stenting has shown to improve patient outcomes. It entails a process of removing plaque deposits from inside arteries in order to restore blood flow to the limbs (peripheral artery disease) or heart (coronary artery disease). It is reimbursed by insurance carriers over and above angioplasty/stents. Ra Medical’s laser atherectomy may be used as a monotherapy or as an adjunct to the current standard of care, thus the Company is not trying to supplant an existing product.

• The global atherectomy devices market is forecast to expand at a CAGR of over 5% from 2016 to 2020. Laser atherectomy is one of the key developments in this space enabling greater efficiencies with fewer complications.

• The RA-308 and DABRA catheter products are applicable to multiple endovascular applications, including crossing chronic total occlusions ([CTOs] totally blocked arteries) in the peripherals, specifically below the knee; in-stent restenosis; other atherectomy needs; coronary artery disease; and lead removal.

• The RA Medical team has over 14 years of experience in building its business with high capital efficiency, and decades of expertise in excimer lasers specifically. Its executive leadership comes from major medical device companies and science and engineering institutions, including Eli Lilly, the Plasma Research Center at MIT, the Institute of Plasma Physics at Nagoya University, Caltech’s Jet Propulsion Laboratory, Intel, Kellogg, Solta Medical, and the U.S. Navy and Marine Corp, among other notable entities. There are almost 70 years of experience in excimer laser and medical device development and manufacturing just between CEO Dean Irwin and R&D Director, Dr. James Laudenslager.

• The Company pursues patents, copyrights, trademarks, and confidentiality/invention assignment agreements to protect its intellectual property rights. Its patent portfolio consists of provisional and utility patent applications for the endovascular technology that have been filed in the U.S. and certain foreign jurisdictions.

• As of March 31, 2016, Ra Medical reported that the Company held cash and cash equivalents of $218,509, with total current assets of over $1.5 million and no debt.